Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Brief Commentary
Cardio Oncology with ACOS
Case Report
Case Series
Conference Review
Consensus Statement
Current Issue
Letter to Editor
Media and News
Molecular Insight Story
New Drug Update
Original Article
Position Paper
Response to the letter
Review Article
Short Communication
View/Download PDF

Translate this page into:

5 (
); 42-43

Important COVID-19 update –New life-threatening syndrome in pediatric patients?

Department of Precision Oncology and Research, Shalby Hospital, Mumbai, Maharashtra, India
Department of Medical Oncology/Hematoncology/BMT, Asian Institute of Medical Sciences, Faridabad, Haryana, India
Department of Medical Oncology, Sir Gangaram Hospital, New Delhi, India
Corresponding author: Purvish Parikh, Department of Precision Oncology and Research, Shalby Hospital, Mumbai, Maharashtra, India.
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Purvish P, Prashant M, Shyam A. Important COVID-19 update –New life-threatening syndrome in pediatric patients? Int J Mol Immuno Oncol 2020;5(2):42-3.

On May 4, 2020, the Department of Health, NY, USA, issued a statement regarding a newly recognized COVID-19 multisystem inflammatory syndrome affecting children.[1] A day later, Mayor Bill de Blasio called it a “concern” in his daily news conference and asked all similar patients below the age of 21 years to be reported urgently.

Presenting features included fever, rash, abdominal pain, and redness of eyes. It seems that some sort of inflammation is responsible for resultant shock and multiorgan failure. This is similar to the report from Italy of inflammatory lung injury seen by them in COVID-19 patients.[2,3]

An 8-year-old health boy reported was normal till the last week of April 2020.[1] At that time, he started having fever and diarrhea, which are both commonly known to be associated with COVID-19 infection. He responding temporarily to Tylenol prescribed by the pediatrician. But he remained weak. Few days later, he was found to have cyanosis, weak pulse, and required CPR at home and was rushed to the hospital, where he was put on ventilatory support. The Cohen Children’s Hospital located in Nassau County, NY, has seen a similar clinical picture in 40 children and Long Island Children’s Hospitalreported the same in a dozen more.Jane Newburger, director of the Kawasaki Program at Boston Children’sHospital, told NBC News this new ailment was being seen in multiple cities throughout the United States.[4]

The transition from being totally well to being so ill as to require ventilatory support is a short 5days. After doing multiple tests, the common thread is COVID-19 positivity. And the intriguing part is that sometimes only the child is positive, there rest of the family living in the same “bubble” are free of the infection.

The symptoms remind us of toxic shock syndrome and/or Kawasaki disease –an autoimmune syndrome activated by viral infections which is known to progress to life-threatening multiorgan damage.[5,6]

These reports show that COVID-19 can be dangerous to children, dispelling the myth thatthe current pandemic was not affecting the younger population.

Following are important messages from the above news:

  1. COVID-19 test was done only after the cardiac arrest in the 8-year child mentioned above, at a time, he was already on ventilatory support

  2. In some of these children, COVID-19 PCR was negative and diagnosis was made on antibody testing

  3. While viruses typically test positive for several weeks, maybe their copy number might be at levels below PCR detection –a phenomenon that is well known in the management of cancers

  4. Whether the antibody tests for IgG or IgM do not seem to matter because titers of both start rising at the same time

  5. Onset of this syndrome could be delayed, by which time the offending infective virus is gone –making it a possible delayed immune dysregulation phenomenon

  6. The mechanism for delayed effects of COVID-19 virus could be similar to the acute respiratory distress syndrome (ARDS) that we have previously seen with dengue, increase in permeability of alveolar-capillary membrane resulting in edema of the alveoli as well as the interstitial spaces causing compromised pulmonary function and hypoxia

  7. This could make COVID-19 shock syndrome the fourth cause (after sepsis, pneumonia, and dengue) of ARDS in pediatric patients admitted to ICU

  8. Early restoration of adequate tissue perfusion and oxygenation will be critical

  9. Simultaneously, attention needs to be paid to avoid unnecessary fluid infusions, lest we flood the lungs and accelerate the ARDS process.

Declaration of patient consent

Patient’s consent not required as there are no patients in this study.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.


  1. Gene expression profiling tests for early-stage invasive breast cancer: A health technology assessment. Ont Health Technol Assess Ser. 2020;20:1-234.
    [Google Scholar]
  2. , , , , , , et al. Patterns and predictors of first and subsequent recurrence in women with early breast cancer. Breast Cancer Res Treat. 2017;165:709-20.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , , , , et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2016;34:1134-50.
    [CrossRef] [PubMed] [Google Scholar]
  4. , , , , , , et al. Estimating the benefits of therapy for early-stage breast cancer: The St. Galleninternational consensus guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30:1541-57.
    [CrossRef] [PubMed] [Google Scholar]
  5. , , , , , , et al. Oncotype DX: Where does it stand in India? J Glob Oncol. 2019;5:1-2.
    [CrossRef] [Google Scholar]
  6. , , , , , , et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol. 2011;29:4273-8.
    [CrossRef] [PubMed] [Google Scholar]

Fulltext Views

PDF downloads
View/Download PDF
Download Citations
Show Sections